Association

[1]  R. Jagsi,et al.  Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. , 2019, Oral oncology.

[2]  S. Grupp,et al.  Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Tu,et al.  Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome , 2019, American journal of hematology.

[4]  K. Fessele,et al.  Financial Support Models: A Case for Use of Financial Navigators in the Oncology Setting. , 2019, Clinical journal of oncology nursing.

[5]  E. Morasso,et al.  Financial Vulnerability: A Case Study Involving a Patient With Head and Neck Cancer. , 2019, Clinical journal of oncology nursing.

[6]  S. Giordano,et al.  Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  M. Perales,et al.  CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma. , 2019, Blood.

[8]  V. Sondak,et al.  The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy , 2019, Clinical Cancer Research.

[9]  S. Peddada,et al.  Understanding financial toxicity in head and neck cancer survivors. , 2019, Oral oncology.

[10]  I. Brownell,et al.  The crippling financial toxicity of cancer in the United States , 2019, Cancer biology & therapy.

[11]  D. Maloney,et al.  HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY , 2019, Blood.

[12]  Jin Gao,et al.  CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia , 2019, Leukemia.

[13]  T. Guo,et al.  Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy , 2019, Annals of Hematology.

[14]  M. Sadelain,et al.  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. , 2019, JCI insight.

[15]  S. Jagannath,et al.  Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma , 2019, The New England journal of medicine.

[16]  Iulian Pruteanu-Malinici,et al.  B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , 2019, The Journal of clinical investigation.

[17]  Haifeng Song,et al.  A safe and potent anti-CD19 CAR T cell therapy , 2019, Nature Medicine.

[18]  Yuan-fang Liu,et al.  Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma , 2019, Proceedings of the National Academy of Sciences.

[19]  Hui Hu,et al.  Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL , 2019, Genom. Proteom. Bioinform..

[20]  L. Sharp,et al.  Cancer‐related financial hardship among head and neck cancer survivors: Risk factors and associations with health‐related quality of life , 2019, Psycho-oncology.

[21]  E. Adjei Boakye,et al.  Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors , 2019, JAMA otolaryngology-- head & neck surgery.

[22]  S. Coughlin,et al.  Cancer survivorship care plans, financial toxicity, and financial planning alleviating financial distress among cancer survivors , 2019, Supportive Care in Cancer.

[23]  A. Benson,et al.  Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies , 2019, Journal of surgical oncology.

[24]  Ping Yang,et al.  Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma , 2019, Cancer Gene Therapy.

[25]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[26]  B. Lei,et al.  A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma , 2018, Journal of Hematology & Oncology.

[27]  D. Neuberg,et al.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma , 2018, Cancer Immunology Research.

[28]  A. Deal,et al.  Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. , 2018, Journal of oncology practice.

[29]  J. Heath,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[30]  M. Höglund,et al.  A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia , 2018, Clinical Cancer Research.

[31]  M. Sadelain,et al.  Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  J. Zhao,et al.  Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia , 2018, American journal of hematology.

[33]  H. Kantarjian,et al.  The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment , 2018, CA: a cancer journal for clinicians.

[34]  P. Li,et al.  A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia , 2018, Journal of Hematology & Oncology.

[35]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[36]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[37]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[38]  Marianne M. Casilla-Lennon,et al.  Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life , 2017, The Journal of urology.

[39]  J. Byrd,et al.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Zhang,et al.  Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[41]  B. Cosmi.  Management of idiopathic venous thromboembolism , 2016, Expert review of cardiovascular therapy.

[42]  M. Ratain,et al.  Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) , 2016, Cancer.

[43]  Syed Abbas Ali,et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.

[44]  F. Fall,et al.  Primary Hyperparathyroidism and Pancreatitis: A Rare Association with Multiple Facets , 2016, International scholarly research notices.

[45]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[46]  Yang Liu,et al.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial , 2016, Clinical Cancer Research.

[47]  J. Waldron,et al.  Prevalence and nature of survivorship needs in patients with head and neck cancer , 2016, Head & neck.

[48]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[49]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[50]  H. Eom,et al.  Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors , 2016, Journal of immunotherapy.

[51]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[52]  N. Meader,et al.  A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation , 2014, Systematic Reviews.

[53]  A. Abernethy,et al.  Self-reported financial burden and satisfaction with care among patients with cancer. , 2014, The oncologist.

[54]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[55]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[57]  G. Leone,et al.  Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients , 2013, British journal of haematology.

[58]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[59]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[60]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[61]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[62]  J. Spence,et al.  Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. , 2010, The Canadian journal of cardiology.

[63]  A. Cohen,et al.  The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. , 2010, Thrombosis research.

[64]  I. Jaiyesimi,et al.  Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. , 2009, Clinical advances in hematology & oncology : H&O.

[65]  U. Mellqvist,et al.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. , 2009, Blood.

[66]  R. Wermers,et al.  Acute pancreatitis in primary hyperparathyroidism: a population-based study. , 2009, The Journal of clinical endocrinology and metabolism.

[67]  T. Holland-Letz,et al.  Pancreatitis Risk in Primary Hyperparathyroidism: Relation to Mutations in the SPINK1 Trypsin Inhibitor (N34S) and the Cystic Fibrosis Gene , 2008, The American Journal of Gastroenterology.

[68]  J. Halterman,et al.  Psychological Functioning and Coping Among Mothers of Children With Autism: A Population-Based Study , 2007, Pediatrics.

[69]  C. Trautwein,et al.  Acute necrotic pancreatitis induced by severe hypercalcaemia due to tacalcitol ointment , 2007, The British journal of dermatology.

[70]  L. Lotspeich,et al.  A Comparison of Health Care Utilization and Costs of Children With and Without Autism Spectrum Disorders in a Large Group-Model Health Plan , 2006, Pediatrics.

[71]  J. Halterman,et al.  Characteristics of School-Age Children with Autism , 2006, Journal of developmental and behavioral pediatrics : JDBP.

[72]  Carmen DeNavas-Walt,et al.  Income, Poverty, and Health Insurance Coverage in the United States: 2005 , 2006 .

[73]  P. Vos,et al.  The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  J. Bladé.  On the "significance" of monoclonal gammopathy of undetermined significance. , 2004, Mayo Clinic proceedings.

[75]  S. Mishra,et al.  Pancreatitis in patients with primary hyperparathyroidism. , 2003, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[76]  Martin Knapp,et al.  Measuring the Parental, Service and Cost Impacts of Children with Autistic Spectrum Disorder: A Pilot Study , 2003, Journal of autism and developmental disorders.

[77]  J. Chambers,et al.  Total Expenditures for Students with Disabilities, 1999-2000: Spending Variation by Disability. Report. Special Education Expenditure Project (SEEP). , 2003 .

[78]  C. Arquizan.  Thrombophlébites cérébrales : aspects cliniques, diagnostic et traitement , 2001 .

[79]  Y. Chapuis.  L’Association francophone de chirurgie endocrinienne , 2001 .

[80]  A. Milam,et al.  Cancer-associated retinopathy. , 1999, Archives of ophthalmology.

[81]  D. West.  Boys and Sexual Abuse: An English Opinion , 1998, Archives of sexual behavior.

[82]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  H. Brincker,et al.  Immunohistologic separation of B‐cell‐positive granulomas from B‐cell‐negative granulomas in paraffin‐embedded tissues with special reference to tumor‐related sarcoid reactions , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[84]  S. Kornguth,et al.  AUTOIMMUNE BASIS FOR VISUAL PARANEOPLASTIC SYNDROME IN PATIENTS WITH SMALL-CELL LUNG CARCINOMA , 1985, The Lancet.

[85]  Bruining Ha,et al.  Primary hyperparathyroidism and pancreatitis. , 1984, The Netherlands journal of surgery.

[86]  D. Archer,et al.  An ultrastructural study of retinal photoreceptor degeneration associated with bronchial carcinoma. , 1984, American journal of ophthalmology.

[87]  A. Roth,et al.  Photoreceptor degeneration. Possible autoimmune disorder. , 1983, Archives of ophthalmology.

[88]  S. Kornguth,et al.  Occurrence of anti‐retinal ganglion cell antibodies in patients with small cell carcinoma of the lung , 1982, Cancer.

[89]  J. V. van Heerden,et al.  Hyperparathyroidism and pancreatitis. Chance or a causal association? , 1980, JAMA.

[90]  W. Hoyt,et al.  Blindness caused by photoreceptor degeneration as a remote effect of cancer. , 1976, American journal of ophthalmology.

[91]  Stephanie Dillard.  King's College , 1867 .

[92]  J. Birkett.  Guy's Hospital , 1841, British medical journal.

[93]  F. Duck,et al.  The London School of Medicine for Women , 2019, Edith and Florence Stoney, Sisters in Radiology.

[94]  J. Serratrice,et al.  Maladie thromboembolique veineuse idiopathique : faut-il rechercher un cancer occulte? , 2018, Revue Médicale Suisse.

[95]  H. Schünemann,et al.  [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[96]  C. Rice,et al.  Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years--United States, 2003-2004. , 2006, MMWR. Morbidity and mortality weekly report.

[97]  J. Drife.  Thromboembolism. , 2003, British medical bulletin.

[98]  D. Jeanbourquin.  SERVICE D'IMAGERIE MEDICALE , 1996 .

[99]  H. Griffiths,et al.  Sarcoidosis and cancer. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[100]  A. Roth,et al.  Management and monitoring of cancer-associated retinopathy. , 1992, Archives of ophthalmology.

[101]  TALFOURD ELY,et al.  University College , 1878, Nature.